Do PEMF mats work? Uncertain pain relief, no evidence for longevity

Same name, very different devices

Some reviews found short-term relief of osteoarthritis pain, but many of the trials have high or unclear risk of bias^1–3. Those trials didn’t show a clear gain in quality of life or overall well-being either^{1, 2}. FDA-reviewed PEMF products, such as bone growth stimulators and prescription devices for postoperative pain and swelling, are specific medical devices^{5, 6}. You can’t assume their results carry over to home mats⁵.

PEMF devices use an electric current to create magnetic fields that vary in intensity⁴. Static magnets sold in wristbands, jewelry, mats or pillows are different: their fields don’t change⁴. According to NIH’s National Center for Complementary and Integrative Health (NCCIH), FDA has approved PEMF for certain conditions⁴. These include fractures that don’t heal with standard medical treatment, and postoperative pain and swelling in superficial soft tissue⁴.

Those approvals cover particular medical devices with particular settings and indications. A home mat sold for relaxation or general wellness can share the PEMF name without having been through either review. So the label on the box says little about the evidence behind a specific product.

Does PEMF help osteoarthritis pain?

Osteoarthritis has the largest body of randomized PEMF trials we found. A 2013 Cochrane review included nine trials in 636 adults with osteoarthritis¹. Participants used electromagnetic field treatment or a sham for 4 to 26 weeks¹.

Pain relief was about 15 points greater on a 0 to 100 scale (mean difference 15.10, 95% CI 9.08 to 21.13)¹. The review concluded that electromagnetic fields probably relieve pain¹. But physical function didn’t differ significantly (mean difference 4.55, 95% CI -2.23 to 11.32)¹. The review’s searches ran only to October 2013¹.

A 2020 meta-analysis in the journal Physical Therapy reviewed 16 placebo-controlled trials with 1,078 participants². It pooled 15 of them². It reported improvements in pain (standardized mean difference 1.06, 95% CI 0.61 to 1.51)². Stiffness (0.37, 95% CI 0.07 to 0.67) and physical function (0.46, 95% CI 0.14 to 0.78) improved too².

But the trials disagreed sharply on pain (I² = 90%)². Only 2 of the 16 were rated at low risk of bias in 6 of 7 domains². The rest were at unclear or high risk in at least one domain². The evidence was limited to short-term effects, and the authors rated its certainty low or very low².

The newest review, published in 2026, pooled nine randomized trials in 457 people with knee osteoarthritis³. The trials were published from 2015 to 2025 and compared PEMF with sham PEMF, another physical therapy or exercise³. At one month, the review found no significant improvement in pain on a visual analog scale or in total WOMAC score³. WOMAC pain improved at 18 to 21 days, but not at one month³.

WOMAC stiffness and daily-activity scores did improve at one month, but objective function tests didn’t³. Seven of the nine trials were rated at high overall risk of bias³. The authors wrote that their pooled differences didn’t meet thresholds for a minimal clinically important difference, even when statistically significant³.

Beyond osteoarthritis, NCCIH says the research suggests electromagnetic therapy can relieve pain and improve function in various musculoskeletal pain conditions⁴. The data are mixed, though⁴. Research hasn’t shown the therapy helps shoulder pain, and the evidence for fibromyalgia pain is very limited and weak⁴.

NCCIH also cites a 2020 review of 21 studies with 1,101 participants⁴. It reported less pain and better function across several conditions⁴. But it found no further pain relief when electromagnetic therapy was added to other physical therapies, such as hot packs, therapeutic ultrasound or TENS⁴.

FDA-reviewed medical uses are a separate category

Noninvasive bone growth stimulators include PEMF devices, along with capacitive coupling, combined magnetic field and low-intensity ultrasound designs. At a 2020 FDA advisory panel meeting, FDA staff described them as Class III devices that require premarket approval⁵. Staff proposed moving them to Class II⁵. Their approved uses are narrow: established nonunions after trauma, adjunctive treatment of certain fresh fractures and congenital pseudarthrosis⁵. They’re also approved as an adjunct to some cervical and lumbar spinal fusions⁵.

FDA staff said there is reasonable assurance of safety and effectiveness for the approved stimulators⁵. They based this on approval data in which fusion rates were higher with treatment than with control or placebo groups⁵. Staff also warned that small changes to the general device type can make the treatment ineffective⁵. That’s why they proposed device-specific controls⁵. The warning cuts against borrowing results from one device to market another.

Nonthermal shortwave therapy is a second medical category⁶. Federal regulation defines it as a prescription device that applies pulsed radiofrequency energy at 13.56 or 27.12 MHz, without generating deep heat⁶. It’s for adjunctive, palliative treatment of postoperative pain and soft-tissue swelling⁶. The device is Class II, with special controls that include testing to characterize the output waveform and a clinical summary showing effectiveness for the intended use⁶. The controls also cover labeling with recommended treatment regimens and a summary of adverse events⁶.

Products sold only for general wellness follow a different path. FDA’s general wellness guidance dates from January 2026⁷. Under it, the agency’s device center (CDRH) doesn’t intend to examine low-risk general wellness products to determine whether they’re devices⁷. Being covered by the policy doesn’t establish that a product has been shown to be safe or effective for its intended use, the guidance says⁷.

The policy applies only to low-risk products⁷. It excludes invasive or implanted products, and technologies that may pose a safety risk without specific controls⁷. It also asks whether FDA’s device center actively regulates products of the same type⁷.

What the evidence does not show

None of the osteoarthritis reviews measured lifespan, mortality, biological age or any marker of cellular energy. They looked at pain, stiffness, physical function and quality of life over weeks to a few months^1–3. We didn’t find a randomized trial in people that measured lifespan, mortality or biological age after PEMF use.

Even within osteoarthritis, broader well-being didn’t clearly improve. The Cochrane review found electromagnetic fields probably make no difference to overall health and well-being (standardized mean difference 0.09, 95% CI -0.36 to 0.54)¹. The 2020 meta-analysis found no statistically significant change in quality of life (1.49, 95% CI -0.06 to 3.04)².

These trials didn’t test claims that PEMF energizes or recharges cells. The idea does show up in regulator files⁸. An FTC warning letter went to a seller of a PEMF system with a full-body mat⁸. It quoted a promotional video saying “if we can keep our cells energized, then the viruses they can’t even penetrate”⁸. That was among the COVID-19 claims the agency said lacked supporting studies⁸.

Results also don’t transfer neatly between devices. The 2026 review described considerable variation in PEMF settings across trials³. Its subgroup results differed by field amplitude and frequency, though some subgroups had very few trials³. The authors called differences between treatment protocols a major barrier to clear conclusions³. And FDA staff said small changes to the general device type can make bone growth stimulation ineffective⁵.

Where benefits were seen, they were short term. The 2020 authors said the evidence was limited to short-term effects². The 2026 authors said their short-term focus prevents conclusions about whether effects last³.

• Longevity, lifespan or biological age: no human trials found
• Cellular energy or mitochondrial function in people: not measured in the pooled trials
• Quality of life and overall well-being in osteoarthritis: no clear improvement
• Long-term pain relief: not established, since most follow-up lasted weeks to months

FTC and FDA actions on PEMF marketing

In May and June 2020, the FTC sent warning letters to several sellers of PEMF devices^8–10. Their marketing said the devices could treat or prevent COVID-19^8–10. One letter quoted videos claiming PEMF “suppresses & blocks the entry of the coronavirus”⁸. Another cited marketing titled “PEMF Therapy for Coronavirus COVID-19”⁹. A third cited blog advice about “initiating or continuing higher intensity PEMF therapies daily to the whole body and/or to the lungs”¹⁰.

Each letter told the seller to stop coronavirus claims immediately and to report back to the FTC within 48 hours^8–10. It also told the seller to review all other product claims and drop any not supported by competent and reliable scientific evidence^8–10. The letters state that claims to prevent, treat or cure disease need that level of evidence, including well-controlled human clinical studies when appropriate^{9, 10}.

FDA has also acted on PEMF hardware marketed for medical uses. In February 2022 it sent a warning letter to the maker of a pulsed electromagnetic field stimulator¹¹. The stimulator had been registered as a biofeedback device¹¹. FDA said it was marketed for stimulation-based treatment without the required premarket approval or clearance¹¹.

The letter cited claims on the company’s website and partner clinics’ websites¹¹. Among them were placing coils on the belly for inflammation and around joints for arthritis and fibromyalgia, and statements about PTSD¹¹. It also listed quality-system failures such as inadequate complaint handling¹¹.

These were warning letters, not court judgments, and they centered on disease and treatment claims. A product’s absence from enforcement records doesn’t mean its claims have been checked.

Is PEMF therapy safe?

In sham-controlled osteoarthritis trials, side effects were similar to sham. In the Cochrane review, four trials with up to 288 participants found no difference in adverse events (risk ratio 1.17, 95% CI 0.72 to 1.92)¹. No serious adverse events were reported¹. Estimates for rare but serious harms were imprecise, though¹. The 2026 review didn’t report adverse events, and it called for safety to be evaluated systematically in future trials³.

NCCIH says both static and electromagnetic therapy appear to be safe for treating pain⁴. Many studies have reported minimal or no negative side effects⁴.

NCCIH also says some magnets may interfere with medical devices such as pacemakers and insulin pumps⁴. Magnetic devices should be removed before an imaging procedure such as MRI⁴. Small magnets should be kept out of children’s reach, because swallowing or inhaling them can be deadly⁴. If you’re pregnant or have a health condition, NCCIH says to talk with a health care provider before using magnetic therapy⁴.

For approved bone growth stimulators, FDA staff listed risks including burns, electrical shock, electromagnetic interference and interaction with fixation hardware⁵. They reported adverse event rates that were low and similar to control groups⁵. These findings come from trials and approved medical devices, not from testing of any particular home mat. NCCIH also cautions against using static magnets or electromagnets bought without a prescription to put off seeing a health care provider⁴. That goes for pain or any other medical problem⁴.

Sources

1. Electromagnetic fields for the treatment of osteoarthritis (Cochrane review CD003523) Cochrane, 2013 · systematic review
2. Effects of Pulsed Electromagnetic Field Therapy on Pain, Stiffness, Physical Function, and Quality of Life in Patients With Osteoarthritis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials Physical Therapy (Oxford University Press), 2020 · meta-analysis
3. Pulsed Electromagnetic Field Therapy in People with Knee Osteoarthritis: A Systematic Review and Meta-Analysis Medicina (MDPI), 2026 · meta-analysis
4. Magnets For Pain: What You Need To Know National Center for Complementary and Integrative Health (NIH), 2023
5. Proposed Reclassification of Non-Invasive Bone Growth Stimulators (Orthopaedic and Rehabilitation Devices Panel presentation, September 8, 2020) US Food and Drug Administration, 2020 · regulator
6. 21 CFR 890.5290 Shortwave diathermy Electronic Code of Federal Regulations · regulator
7. General Wellness: Policy for Low Risk Devices (guidance for industry and FDA staff, January 2026) US Food and Drug Administration, 2026 · regulator
8. Warning letter to iMRS2000.com about COVID-19 claims (May 11, 2020) Federal Trade Commission, 2020 · regulator
9. Warning letter to BioBalance PEMF about COVID-19 claims (June 1, 2020) Federal Trade Commission, 2020 · regulator
10. Warning letter to PEMF Wellness Technology about COVID-19 claims (June 3, 2020) Federal Trade Commission, 2020 · regulator
11. Warning letter to NeuroField, Inc. (February 28, 2022) US Food and Drug Administration, 2022 · regulator